Drug Profile

HPN 823

Alternative Names: DLL3 TriTAC; HPN823

Latest Information Update: 15 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

11 Mar 2024 Harpoon Therapeutics has been acquired by Merck and Co
28 Dec 2022 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA (Parenteral)
30 May 2019 Harpoon Therapeutics announces intention to file IND application to US FDA for Small cell lung cancer in 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com